Changes in serum sex steroid levels during megestrol acetate therapy

Rodney Pommier, E. A. Woltering, W. S. Fletcher

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    We hypothesized that megestrol acetate (MA) may work on breast carcinoma by inducing changes in serum sex steroid levels. We prospectively measured levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone (DHEA), estrone (E1), and estradiol (E2) in 18 postmenopausal women before and during megestrol acetate therapy. MA significantly suppressed serum FSH, LH, DHEA and E1 levels. However, this was accompanied by a marked increase in serum E2 levels as measured by radioimmunoassay performed on whole serum. MA did not cross-react with the anti-E2 antibodies used in the assay. Elevated E2 levels also occurred in oophorectomized and/or adrenalectomized patients indicating the ovary and adrenal are not the source of the elevated E2 levels. We conclude that MA may be metabolized to oestrogenic compounds that crossreact with antibodies to E2, explaining the elevated E2 levels observed. The effects of these oestrogenic metabolites on breast carcinoma are unknown.

    Original languageEnglish (US)
    Pages (from-to)351-359
    Number of pages9
    JournalSurgical Oncology
    Volume3
    Issue number6
    DOIs
    StatePublished - 1994

    Fingerprint

    Megestrol Acetate
    Steroids
    Serum
    Dehydroepiandrosterone
    Follicle Stimulating Hormone
    Luteinizing Hormone
    Breast Neoplasms
    Therapeutics
    Estrone
    Radioimmunoassay
    Anti-Idiotypic Antibodies
    Ovary
    Estradiol
    Antibodies

    Keywords

    • breast neoplasms
    • hormone therapy
    • megestrol acetate
    • neuroendocrine axis
    • radioimmunoassay
    • sex steroids

    ASJC Scopus subject areas

    • Oncology
    • Surgery

    Cite this

    Changes in serum sex steroid levels during megestrol acetate therapy. / Pommier, Rodney; Woltering, E. A.; Fletcher, W. S.

    In: Surgical Oncology, Vol. 3, No. 6, 1994, p. 351-359.

    Research output: Contribution to journalArticle

    Pommier, Rodney ; Woltering, E. A. ; Fletcher, W. S. / Changes in serum sex steroid levels during megestrol acetate therapy. In: Surgical Oncology. 1994 ; Vol. 3, No. 6. pp. 351-359.
    @article{bc3e025c214c4bb9817dc8420361b638,
    title = "Changes in serum sex steroid levels during megestrol acetate therapy",
    abstract = "We hypothesized that megestrol acetate (MA) may work on breast carcinoma by inducing changes in serum sex steroid levels. We prospectively measured levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone (DHEA), estrone (E1), and estradiol (E2) in 18 postmenopausal women before and during megestrol acetate therapy. MA significantly suppressed serum FSH, LH, DHEA and E1 levels. However, this was accompanied by a marked increase in serum E2 levels as measured by radioimmunoassay performed on whole serum. MA did not cross-react with the anti-E2 antibodies used in the assay. Elevated E2 levels also occurred in oophorectomized and/or adrenalectomized patients indicating the ovary and adrenal are not the source of the elevated E2 levels. We conclude that MA may be metabolized to oestrogenic compounds that crossreact with antibodies to E2, explaining the elevated E2 levels observed. The effects of these oestrogenic metabolites on breast carcinoma are unknown.",
    keywords = "breast neoplasms, hormone therapy, megestrol acetate, neuroendocrine axis, radioimmunoassay, sex steroids",
    author = "Rodney Pommier and Woltering, {E. A.} and Fletcher, {W. S.}",
    year = "1994",
    doi = "10.1016/0960-7404(94)90074-4",
    language = "English (US)",
    volume = "3",
    pages = "351--359",
    journal = "Surgical Oncology",
    issn = "0960-7404",
    publisher = "Elsevier BV",
    number = "6",

    }

    TY - JOUR

    T1 - Changes in serum sex steroid levels during megestrol acetate therapy

    AU - Pommier, Rodney

    AU - Woltering, E. A.

    AU - Fletcher, W. S.

    PY - 1994

    Y1 - 1994

    N2 - We hypothesized that megestrol acetate (MA) may work on breast carcinoma by inducing changes in serum sex steroid levels. We prospectively measured levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone (DHEA), estrone (E1), and estradiol (E2) in 18 postmenopausal women before and during megestrol acetate therapy. MA significantly suppressed serum FSH, LH, DHEA and E1 levels. However, this was accompanied by a marked increase in serum E2 levels as measured by radioimmunoassay performed on whole serum. MA did not cross-react with the anti-E2 antibodies used in the assay. Elevated E2 levels also occurred in oophorectomized and/or adrenalectomized patients indicating the ovary and adrenal are not the source of the elevated E2 levels. We conclude that MA may be metabolized to oestrogenic compounds that crossreact with antibodies to E2, explaining the elevated E2 levels observed. The effects of these oestrogenic metabolites on breast carcinoma are unknown.

    AB - We hypothesized that megestrol acetate (MA) may work on breast carcinoma by inducing changes in serum sex steroid levels. We prospectively measured levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone (DHEA), estrone (E1), and estradiol (E2) in 18 postmenopausal women before and during megestrol acetate therapy. MA significantly suppressed serum FSH, LH, DHEA and E1 levels. However, this was accompanied by a marked increase in serum E2 levels as measured by radioimmunoassay performed on whole serum. MA did not cross-react with the anti-E2 antibodies used in the assay. Elevated E2 levels also occurred in oophorectomized and/or adrenalectomized patients indicating the ovary and adrenal are not the source of the elevated E2 levels. We conclude that MA may be metabolized to oestrogenic compounds that crossreact with antibodies to E2, explaining the elevated E2 levels observed. The effects of these oestrogenic metabolites on breast carcinoma are unknown.

    KW - breast neoplasms

    KW - hormone therapy

    KW - megestrol acetate

    KW - neuroendocrine axis

    KW - radioimmunoassay

    KW - sex steroids

    UR - http://www.scopus.com/inward/record.url?scp=0028659194&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0028659194&partnerID=8YFLogxK

    U2 - 10.1016/0960-7404(94)90074-4

    DO - 10.1016/0960-7404(94)90074-4

    M3 - Article

    C2 - 7773452

    AN - SCOPUS:0028659194

    VL - 3

    SP - 351

    EP - 359

    JO - Surgical Oncology

    JF - Surgical Oncology

    SN - 0960-7404

    IS - 6

    ER -